Experimental POTS drug targets racing heart in first human test

NCT ID NCT06593600

Completed Symptom relief Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests a single dose of an experimental drug called REGN7544 in 82 people with Postural Orthostatic Tachycardia Syndrome (POTS). The goal is to see if the drug safely reduces the rapid heart rate that happens when standing up. Researchers will also check for side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Orthostatic Intolerance postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Indiana University Health Neuroscience Center

Indianapolis, Indiana, 46202, United States
Innovative Research of West Florida, Inc.

Clearwater, Florida, 33756, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mercy Gilbert Medical Center

Gilbert, Arizona, 85297, United States
New York University Langone

New York, New York, 10016, United States
North County Neurology Associates

Carlsbad, California, 92011, United States
Saint Luke's MidAmerica Heart Institute

Kansas City, Missouri, 64111, United States
Southern California Heart Specialists

Pasadena, California, 91105, United States
Stanford University

Palo Alto, California, 94304, United States
University of Calgary

Calgary, Alberta, T2N 4Z6, Canada
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
University of Utah

Salt Lake City, Utah, 84108, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Yale University

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.